A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection.

MLA

Chang, Kuo-Chin, et al. “A Polymorphism in Interferon L3 Is an Independent Risk Factor for Development of Hepatocellular Carcinoma after Treatment of Hepatitis C Virus Infection.” Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association, vol. 13, no. 5, May 2015, pp. 1017–24. EBSCOhost, https://doi.org/10.1016/j.cgh.2014.10.035.

APA

Chang, K.-C., Tseng, P.-L., Wu, Y.-Y., Hung, H.-C., Huang, C.-M., Lu, S.-N., Wang, J.-H., Lee, C.-M., Chen, C.-H., Tsai, M.-C., Yen, Y.-H., Lin, M.-T., Wu, C.-K., Huang, C.-C., Chen, H.-H., & Hu, T.-H. (2015). A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection. Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association, 13(5), 1017–1024. https://doi.org/10.1016/j.cgh.2014.10.035

Chicago

Chang, Kuo-Chin, Po-Lin Tseng, Yi-Ying Wu, Hung-Chao Hung, Chao-Min Huang, Sheng-Nan Lu, Jing-Houng Wang, et al. 2015. “A Polymorphism in Interferon L3 Is an Independent Risk Factor for Development of Hepatocellular Carcinoma after Treatment of Hepatitis C Virus Infection.” Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association 13 (5): 1017–24. doi:10.1016/j.cgh.2014.10.035.